Perspectives of compounding pharmacists on alcohol-based hand sanitizer production and utilization for COVID-19 prevention in Addis Ababa, Ethiopia: A descriptive phenomenology study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
08
2020
accepted:
29
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
13
5
2021
Statut:
epublish
Résumé
Globally, the safety of patients and healthcare providers is at risk due to health care-associated infections (HCAIs). World Health Organization and the Centers for Disease Control and Prevention recommend using alcohol-based hand rub (ABHR) for hand hygiene in healthcare settings to prevent HCAIs. Irrational use of ABHR will have undesirable consequences including wastage of products, exposure of healthcare providers to infections and emergence of microbial resistance to the alcohol in hand sanitizers. This study aimed to explore the perspective and experiences of compounding pharmacists on production and utilization of ABHR solution for coronavirus disease in 2019 (COVID-19) prevention in public hospitals of Addis Ababa, Ethiopia. A descriptive qualitative study using in-depth interview of 13 key-informants serving as compounding pharmacists in public hospitals of Addis Ababa, Ethiopia, was conducted. The study participants were identified and selected by purposive sampling. All transcribed interviews were subjected to thematic analysis and transcripts were analyzed manually. The compounding pharmacists in this study had a mean age of 30.6 (±3.1) years and nine of the thirteen participants were men. Ten participants believed that the compounding practice in their respective sites followed the principles of good compounding practice. More than half of the participants did not believe that ABHR products were used rationally in health facilities. They argued that users did not have enough awareness when and how to use sanitizers. Most of the interviewees reported that compounding personnel had no formal training on ABHR solution production. Study participants suggested incentive mechanisms and reimbursements for experts involved in the compounding of ABHR solutions. Three of the compounding pharmacists indicated that ABHR production in their setting lack compliance to good compounding practice due to inadequate compounding room, quality control tests, manpower and equipment. Despite this, most study participants preferred the in-house ABHR products than the commercially available ones. Thus, training, regular monitoring and follow-up of the hospital compounding services can further build staff confidence.
Sections du résumé
BACKGROUND
Globally, the safety of patients and healthcare providers is at risk due to health care-associated infections (HCAIs). World Health Organization and the Centers for Disease Control and Prevention recommend using alcohol-based hand rub (ABHR) for hand hygiene in healthcare settings to prevent HCAIs. Irrational use of ABHR will have undesirable consequences including wastage of products, exposure of healthcare providers to infections and emergence of microbial resistance to the alcohol in hand sanitizers. This study aimed to explore the perspective and experiences of compounding pharmacists on production and utilization of ABHR solution for coronavirus disease in 2019 (COVID-19) prevention in public hospitals of Addis Ababa, Ethiopia.
METHODS
A descriptive qualitative study using in-depth interview of 13 key-informants serving as compounding pharmacists in public hospitals of Addis Ababa, Ethiopia, was conducted. The study participants were identified and selected by purposive sampling. All transcribed interviews were subjected to thematic analysis and transcripts were analyzed manually.
FINDINGS
The compounding pharmacists in this study had a mean age of 30.6 (±3.1) years and nine of the thirteen participants were men. Ten participants believed that the compounding practice in their respective sites followed the principles of good compounding practice. More than half of the participants did not believe that ABHR products were used rationally in health facilities. They argued that users did not have enough awareness when and how to use sanitizers. Most of the interviewees reported that compounding personnel had no formal training on ABHR solution production. Study participants suggested incentive mechanisms and reimbursements for experts involved in the compounding of ABHR solutions.
CONCLUSION
Three of the compounding pharmacists indicated that ABHR production in their setting lack compliance to good compounding practice due to inadequate compounding room, quality control tests, manpower and equipment. Despite this, most study participants preferred the in-house ABHR products than the commercially available ones. Thus, training, regular monitoring and follow-up of the hospital compounding services can further build staff confidence.
Identifiants
pubmed: 33914768
doi: 10.1371/journal.pone.0250020
pii: PONE-D-20-24316
pmc: PMC8084187
doi:
Substances chimiques
Alcohols
0
Hand Sanitizers
0
Ethanol
3K9958V90M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250020Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Hosp Infect. 2015 Aug;90(4):338-43
pubmed: 25990195
Qual Health Res. 2007 Dec;17(10):1372-80
pubmed: 18000076
Infect Control Hosp Epidemiol. 2007 Dec;28(12):1323-7
pubmed: 17994510
J Pharm Policy Pract. 2018 Apr 11;11:10
pubmed: 29651337
Sci Transl Med. 2018 Aug 1;10(452):
pubmed: 30068573
Res Social Adm Pharm. 2021 Jan;17(1):1807-1812
pubmed: 32546449
Res Social Adm Pharm. 2021 Feb;17(2):480-482
pubmed: 32241695
Bull World Health Organ. 2013 Dec 1;91(12):963-9
pubmed: 24347736
Infect Control Hosp Epidemiol. 2010 Mar;31(3):283-94
pubmed: 20088678
J Hosp Infect. 2008 Apr;68(4):285-92
pubmed: 18329137
Infect Control Hosp Epidemiol. 2014 Sep;35 Suppl 2:S155-78
pubmed: 25376074
MMWR Recomm Rep. 2002 Oct 25;51(RR-16):1-45, quiz CE1-4
pubmed: 12418624
Lancet Infect Dis. 2013 Oct;13(10):843-51
pubmed: 23972825
Lancet. 2002 Apr 27;359(9316):1489-90
pubmed: 11988252